亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

隨州市紅旗化工有限公司  

醫藥原料醫藥中間體原料藥

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:閆先生
  • 電話:0722-3257386
  • 傳真:0722-3257381
  • QQ:1374834438
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 肌苷 CAS號: 58-63-9
肌苷 CAS號: 58-63-9
單價 面議對比
詢價 暫無
發貨 湖北隨州市付款后3天內
型號 58-63-9
過期 長期有效
更新 2020-06-18 10:08
 
詳細信息
肌苷
CAS號: 58-63-9
中文同義詞: 9-D-核糖次黃嘌呤;次黃苷;次黃嘌呤核苷;肌甙;肌苷;9-β-D-呋喃核糖基次黃嘌呤;次黃嘌呤肌苷;次黃苷/肌苷
英文名稱: Inosine
英文同義詞: Atorel;beta-D-Ribofuranoside, hypoxanthine-9;beta-Inosine;HXR;Hypoxanthine D-riboside;Hypoxanthine, 9-beta-D-ribofuranosyl-;hypoxanthined-riboside;hypoxanthinenucleoside
分子式: C10H12N4O5
分子量: 268.23
EINECS號: 200-390-4
標準:cp2005
含量:98-102%
化學性質  本品為白色結晶性粉末;無臭;味微苦。
用途 : 生化研究。醫藥用于促進白細胞增長
包裝:25kg/桶
©2025 隨州市紅旗化工有限公司 版權所有   技術支持:化工網   訪問量:31096  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |